Published February 2022 | Version v1
Journal article Metadata-only

Preclinical evaluation of 188Re-HYNIC-PSMA as a novel therapeutic agent

Creators

  • 1. Sharif University of Technology, Tehran (Iran, Islamic Republic of). Department of Energy Engineering
  • 2. Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of). Radiation Application Research School

Description

In this study, optimized preparation, quality control, cell assessments and biostribution of 188Re-HYNIC-PSMA in normal rats and tumor bearing mice are studied. Optimized conditions for radiolabeling were evaluated and radiochemical purity (> 99%) was investigated using ITLC and HPLC methods. 188Re-HYNIC-PSMA was stable both in PBS (4 °C) and in human serum (37 °C) even after 48 h. The results showed the complex was cleared from the blood very fast via urinary track. This new radiolabeled compound has a high potential to be considered as an agent for the treatment of patients with PSMA expressing tumors however more biological studies are still needed. (author)

Additional details

Publishing Information

Journal Title
Journal of Radioanalytical and Nuclear Chemistry
Journal Volume
331
Journal Issue
2
Journal Page Range
p. 841-849
ISSN
0236-5731
CODEN
JRNCDM

INIS

Country of Publication
Hungary
Country of Input or Organization
Hungary
INIS RN
53031390
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ANTIGENS; LABELLED COMPOUNDS; MEMBRANES; PROSTATE; RHENIUM 188; THERAPY
Descriptors DEC
BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BODY; GLANDS; HEAVY NUCLEI; HOURS LIVING RADIOISOTOPES; INTERNAL CONVERSION RADIOISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; MALE GENITALS; MEDICINE; MINUTES LIVING RADIOISOTOPES; NUCLEI; ODD-ODD NUCLEI; ORGANS; RADIOISOTOPES; RHENIUM ISOTOPES

Optional Information

Notes
21 refs.